Lv21
120 积分 2020-11-26 加入
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial
26天前
已完结
根治性放化疗后颈段食管癌长期生存者生活质量的多维度评估
26天前
已完结
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
1个月前
已完结
Esophageal Cancer
1个月前
已完结
The Society of Thoracic Surgeons (2026) Expert Consensus Document on Management of Esophageal Perforation
1个月前
已关闭
Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study)
2个月前
已完结
A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma
2个月前
已完结
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study
3个月前
已完结
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
3个月前
已完结
Limertinib: First Approval
3个月前
已完结
皖公网安备34019202002308
